Recovery Peptides Compared: BPC-157 vs TB-500 and More in Europe (2026)

BPC-157 attracts wide attention for tendon, ligament, muscle and gut research. Yet most published work uses cells or animals. A 2025 evidence review found one small, uncontrolled human report among 36 included studies. Therefore, the human evidence does not support broad recovery claims.

Moreover, BPC-157 has no EU or UK marketing authorisation. FDA materials also note limited safety information and possible quality or immune-response concerns for compounded products.

Online sellers often group TB-500 with BPC-157. However, TB-500 is a short fragment linked to thymosin beta-4. It is not the same molecule as the full-length protein used in much of the clinical literature.

In addition, FDA reviewers said they found no human exposure data for drug products containing the TB-500 fragment. The agency discussed TB-500 at its July 2026 compounding meeting, but that review did not make it an approved drug.

GHK-Cu differs because topical cosmetic formulas have some human study history. Even so, topical skin data cannot prove that an injected product is safe or effective. Route of use matters.

As a result, readers should separate cosmetic products from injectable research compounds. FDA materials list non-injectable GHK-Cu as under evaluation for compounding, while the agency flags injectable forms for added safety concerns.

KPV is a short peptide studied in early inflammation models. Researchers have explored gut and skin pathways, but these findings remain mainly preclinical. In fact, FDA reviewers reported no identified human exposure data for KPV drug products.

Therefore, KPV marketing runs ahead of the evidence. The July 2026 FDA compounding discussion also did not create an approval in the US or Europe.

MOTS-c is a mitochondrial-derived peptide. As such, it belongs in metabolic research rather than a simple soft-tissue recovery group. Early laboratory work looks at energy use, obesity and bone pathways.

However, FDA reviewers said they found no human exposure data for compounded MOTS-c drug products. Also, MOTS-c has no EU or UK marketing authorisation.

Semax and Selank appear in peptide searches, yet they target a different field. Researchers study them for brain and nervous-system effects rather than tissue repair. Their evidence base also comes largely from Russia and remains hard to compare with modern European approval files.

Meanwhile, neither compound has an EU or UK marketing authorisation. For that reason, they should not share the same evidence label as an approved medicine.

Selected GLP-1 medicines provide a useful control group. For example, the EU has authorised Ozempic and Wegovy products containing semaglutide. It has also authorised Mounjaro, which contains tirzepatide. These products have defined uses, product information and ongoing safety checks.

In contrast, the research compounds above do not share that approval record. See our approved medicines vs research compounds guide for a clearer regulatory comparison.